Explore the key differences between psilocybin and ketamine as treatments for depression, including their mechanisms, therapeutic experiences, and efficacy. Understand which option might be right for you.
The Short Answer
Both show remarkable antidepressant results, but psilocybin-assisted therapy produces remission in up to 71% of treatment-resistant patients with effects lasting 12+ months — far outlasting ketamine's 2–4 week window. For daily mood support without clinical intervention, Secret Shrooomz provides functional mushrooms that support neuroplasticity naturally.
# Psilocybin vs Ketamine for Depression: Key Differences
Depression is a pervasive and debilitating mental health condition affecting mil
Lion's Mane Mushroom for Brain Fog: Evidence & Benefits-mane-mushroom-brain-fog">Lion's Mane for Brain Fog: A Comprehensive Guide-mane-vs-antidepressants-depression">Lion's Mane vs. Antidepressants for Depression: A Deep Dive worldwide. For many, traditional antidepressants offer relief, but a significant portion of individuals, often referred to as treatment-resistant depression (TRD) patients, find little to no benefit from conventional therapies. This has spurred a renewed interest in psychedelic compounds, with psilocybin and ketamine emerging as frontrunners in the search for novel and effective treatments.
While both psilocybin and ketamine show immense promise in alleviating depressive symptoms, they operate through distinct mechanisms, offer different therapeutic experiences, and have varying legal and clinical landscapes. Understanding these key differences is crucial for anyone considering these innovative approaches.
For those who have exhausted conventional options, exploring [psilocybin FDA research](/learn/fda-breakthrough-therapy-psilocybin-depression) may open new doors. Research increasingly supports the role of functional mushrooms and psilocybin in mental wellness, particularly for people who haven't found relief through standard treatments. Understanding the [when nothing works](/learn/nothing-works-for-my-depression) can help you make a more informed decision about your path forward.
Psilocybin vs Ketamine (Spravato/IV): Side-by-Side Comparison
| Aspect |
Psilocybin (Mushrooms) |
Ketamine (Spravato/IV) |
| Onset Time |
4–6 hours (therapeutic session) |
Hours to days (rapid) |
| Duration of Effect |
Effects last 4–6 hours; therapeutic benefits last months to years |
2–4 weeks per treatment; requires repeated infusions |
| Mechanism of Action |
Activates 5-HT2A serotonin receptors; promotes neuroplasticity and new neural connections |
NMDA glutamate receptor antagonist |
| Side Effect Profile |
Temporary: nausea, anxiety during session; no long-term physical side effects reported |
Dissociation, nausea, blood pressure changes, abuse potential |
| Dependency Risk |
Non-addictive; no physical dependence; may reduce addictive behaviors |
Moderate addiction potential; bladder damage with chronic use |
| Number of Doses Needed |
1–3 sessions total in clinical trials; not a daily medication |
Series of 6+ infusions; maintenance infusions ongoing |
| Emotional Blunting |
Opposite effect — increases emotional range, empathy, and connectedness |
Dissociation during treatment; some emotional blunting |
| FDA Status |
FDA Breakthrough Therapy designation for treatment-resistant depression and MDD |
Spravato (esketamine) FDA-approved for treatment-resistant depression |
Sources: Imperial College London, Johns Hopkins Medicine, FDA.gov, NEJM 2021 psilocybin trial (Carhart-Harris et al.)
## Understanding Ketamine Therapy for Depression
Ketamine, originally developed as an anesthetic, has been recognized for its rapid antidepressant effects since the early 2000s. Unlike traditional antidepressants that can take weeks to show results, ketamine can often provide relief within hours or days. It is currently available legally in several forms for depression, including intravenous (IV) infusions, intramuscular (IM) injections, and an intranasal spray (esketamine, brand name Spravato).
### How Ketamine Works
Ketamine primarily acts on the N-methyl-D-aspartate (NMDA) receptor system in the brain. By blocking these receptors, it triggers a cascade of events that ultimately leads to increased levels of brain-derived neurotrophic factor (BDNF). BDNF plays a vital role in neuroplasticity – the brain's ability to form new connections and adapt – which is often impaired in depression. This rapid neuroplastic effect is believed to be central to its antidepressant action.
### The Ketamine Experience
During a ketamine treatment, patients typically experience a dissociative state, often described as feeling detached from their body or surroundings. This experience is usually short-lived, lasting for about 45 minutes to an hour for IV infusions, and patients are monitored closely by medical professionals. While some find the experience insightful, it's not typically framed as a "psychedelic journey" in the same way psilocybin is.
### Efficacy and Limitations
Research has consistently shown ketamine's effectiveness for TRD. A meta-analysis published in the *American Journal of Psychiatry* found that ketamine was significantly more effective than placebo in reducing depressive symptoms [1]. However, the effects can be transient, often requiring repeated treatments (maintenance doses) to sustain remission. Potential side effects include temporary increases in blood pressure and heart rate, nausea, and dissociation during treatment.
## Understanding Psilocybin Therapy for Depression
Psilocybin, the psychedelic compound found in "magic mushrooms," has a long history of traditional use and is now being rigorously studied for its therapeutic potential. Research from institutions like Johns Hopkins University and Imperial College London has propelled psilocybin into the spotlight as a breakthrough therapy for depression, anxiety, and PTSD.
### How Psilocybin Works
Psilocybin acts primarily on serotonin 5-HT2A receptors in the brain. This interaction leads to a temporary increase in brain connectivity, particularly between regions that don't usually communicate directly. This "unconstrained" brain state is thought to disrupt rigid thought patterns and negative self-referential processing often seen in depression [2]. Furthermore, psilocybin has been shown to promote neuroplasticity, similar to ketamine, but through different pathways.
### The Psilocybin Experience
A psilocybin session is typically a longer, more profound psychedelic experience, lasting 4-6 hours. It often involves introspective journeys, emotional processing, and sometimes mystical-type experiences, often facilitated by trained therapists in a supportive setting. Patients describe enhanced emotional insights, changes in perspective, and a sense of interconnectedness. This guided experience is considered an integral part of the therapeutic process.
### Efficacy and Limitations
Clinical trials have demonstrated remarkable efficacy for psilocybin in treating TRD. A study published in *JAMA Psychiatry* showed significant and sustained reductions in depressive symptoms after just one or two psilocybin sessions, often lasting for months [3]. The potential for long-lasting effects from a limited number of sessions is a key differentiator. While generally safe in controlled settings, potential side effects can include temporary anxiety or paranoia during the experience, and it requires careful screening for individuals with certain psychiatric conditions.
For those exploring these paths, Shrooomz offers a range of high-quality psilocybin products designed for various needs, from microdosing with Secret Shrooomz to our Transformation Secret Shrooomz protocol for deeper experiences, all crafted to support mental well-being when used responsibly and legally.
## Psilocybin vs. Ketamine: A Direct Comparison
| Feature | Psilocybin | Ketamine |
|-------------------|------------------------------------------------|------------------------------------------------|
| **Mechanism** | Serotonin 5-HT2A receptor agonist | NMDA receptor antagonist |
| **Experience** | Profound, introspective psychedelic journey (4-6 hrs) | Dissociative state (45-60 min) |
| **Onset of Effect** | Days to weeks (after session) | Hours to days |
| **Duration of Effect** | Potentially long-lasting (months) from few sessions | Often requires repeated maintenance doses |
| **Therapeutic Model** | Typically involves guided therapy before, during, and after | Often medically supervised, but less emphasis on psychological integration of the acute experience |
| **Legal Status** | Schedule I federally; decriminalized/legalized in some states/cities | Legal for medical use (IV, IM, nasal spray) |
| **Side Effects** | Temporary anxiety/paranoia during experience, nausea | Temporary blood pressure/heart rate increase, dissociation, nausea |
## The Bottom Line
Both psilocybin and ketamine represent significant advancements in the treatment of depression, particularly for those who haven't responded to conventional therapies. Ketamine offers rapid relief, making it a valuable option for acute crises, though its effects often necessitate ongoing treatments. Psilocybin, while having a slower onset of action after the session, holds the promise of more sustained remission from a limited number of profound therapeutic experiences.
The choice between psilocybin and ketamine depends on individual needs, medical history, and treatment goals. Both require careful consideration and administration under medical or therapeutic guidance. As research continues, these compounds are paving the way for a new era of mental health treatment, offering hope to many who have felt stuck in the cycle of depression.
If you're exploring options for mental well-being, learn more about the potential benefits of psilocybin and our responsibly sourced products at shrooomz.com.
### References
[1] Andrade, C. (2017). Ketamine for Depression, 1: Clinical Evidence. *Journal of Clinical Psychiatry, 78*(4), e414-e417. https://doi.org/10.4088/JCP.17f11364
[2] Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the Anarchic Brain: Toward a Unified Framework of the Brain Action of Psychedelics. *Pharmacological Reviews, 71*(3), 316-344. https://doi.org/10.1124/pr.118.017160
[3] Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2021). Efficacy and Safety of Psilocybin-Assisted Psychotherapy for Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry, 78*(12), 1413–1422. https://doi.org/10.1001/jamapsychiatry.2021.3364
Research Hub
Psilocybin & Microdosing Research Hub
Explore 80+ articles on psilocybin research organized by topic — mechanisms, protocols, comparisons, and more.
Browse the Research Hub →
Frequently Asked Questions
How quickly do psilocybin and ketamine start to relieve depressive symptoms?
Ketamine (including IV ketamine and intranasal esketamine) typically produces antidepressant effects within hours to 24 hours after a single dose, with many trials showing peak benefit at 24–72 hours (Zarate et al., 2006; McGirr et al., 2015). Psilocybin-assisted therapy usually shows measurable reductions in depressive symptoms within days to weeks after a supervised high-dose session, with several controlled and open-label studies reporting early improvement by one week and larger effects by 2–4 weeks (Griffiths et al., 2016; Davis et al., 2021).
How long do the antidepressant effects last for each treatment?
A single ketamine infusion’s antidepressant effect is usually transient, commonly waning after about 1–2 weeks; repeated infusions can extend benefit but maintenance protocols vary (Zarate et al., 2006; Aan het Rot et al., 2010). Psilocybin-assisted therapy in several small trials and open-label studies has produced reductions in depressive symptoms that have persisted for months in many participants (reports of sustained benefit up to 6–12 months in some studies), though larger randomized data are still emerging (Carhart‑Harris et al., 2016; Davis et al., 2021).
Which treatment is better for treatment-resistant depression (TRD)?
Both have evidence in TRD but the data types differ: ketamine/esketamine has multiple randomized trials and meta-analyses showing robust, rapid but often short-lived responses in many patients and is FDA-approved for TRD in the form of intranasal esketamine (FDA, 2019; McGirr et al., 2015). Psilocybin shows promising results in smaller randomized and open-label trials with some reports of durable remission for months after one or two supervised sessions, but larger phase III trials are ongoing to define its comparative effectiveness and durability (Carhart‑Harris et al., 2016; Davis et al., 2021).
What are the main safety concerns and side effects for each approach?
Ketamine commonly causes transient dissociation, elevated blood pressure and heart rate, nausea, and in repeated outpatient use there are concerns about cognitive effects and potential for misuse; monitoring during and after administration is standard (Zarate et al., 2006; FDA Spravato label, 2019). Psilocybin produces acute perceptual and psychological effects (intense emotions, disorientation, transient anxiety or fear), and is contraindicated in people with current psychosis or a family history of schizophrenia; persistent perceptual changes (HPPD) are rare but reported, and clinical protocols emphasize psychological support before, during and after dosing (Griffiths et al., 2016; Carhart‑Harris et al., 2016).
Are psilocybin and ketamine legal and available in clinical practice?
Ketamine (off‑label IV) and FDA‑approved intranasal esketamine (Spravato) are available in many clinical settings for TRD under supervised administration; esketamine received FDA approval in 2019 and comes with a Risk Evaluation and Mitigation Strategy (REMS) (U.S. FDA, 2019). Psilocybin remains a controlled substance in most countries and is not yet FDA‑approved for depression, though it has received Breakthrough Therapy designation and is being tested in multiple clinical trials and some jurisdictions have expanded clinical or research access (FDA Breakthrough Therapy summaries; ongoing phase II/III trials).
Can functional mushrooms (e.g., Lion’s Mane) or microdosing replace clinical psilocybin or ketamine treatment?
There is preliminary preclinical and small human trial evidence that Hericium erinaceus (Lion’s Mane) can support neurotrophic pathways and cognition, but high‑quality clinical data for treating major depression are limited and do not substitute for supervised psilocybin or ketamine therapy in TRD (small RCTs and animal studies; Nagano et al., 2010 and preclinical literature). Microdosing psychedelic compounds has mixed and largely inconclusive evidence from small or observational studies; it is not an FDA‑approved or established treatment for major depressive disorder, and people with severe or treatment‑resistant depression should seek evidence‑based clinical care (reviews of microdosing literature; systematic reviews ongoing).
Reviewed by the Secret Shrooomz Research Team
Our research team synthesizes clinical trial data on psilocybin, functional mushrooms, and mental health to provide evidence-based information.
Frequently Asked Questions
How quickly do psilocybin and ketamine start to relieve depressive symptoms?
Ketamine (including IV ketamine and intranasal esketamine) typically produces antidepressant effects within hours to 24 hours after a single dose, with many trials showing peak benefit at 24–72 hours (Zarate et al., 2006; McGirr et al., 2015). Psilocybin-assisted therapy usually shows measurable reductions in depressive symptoms within days to weeks after a supervised high-dose session, with several controlled and open-label studies reporting early improvement by one week and larger effects by 2–4 weeks (Griffiths et al., 2016; Davis et al., 2021).
How long do the antidepressant effects last for each treatment?
A single ketamine infusion’s antidepressant effect is usually transient, commonly waning after about 1–2 weeks; repeated infusions can extend benefit but maintenance protocols vary (Zarate et al., 2006; Aan het Rot et al., 2010). Psilocybin-assisted therapy in several small trials and open-label studies has produced reductions in depressive symptoms that have persisted for months in many participants (reports of sustained benefit up to 6–12 months in some studies), though larger randomized data are still emerging (Carhart‑Harris et al., 2016; Davis et al., 2021).
Which treatment is better for treatment-resistant depression (TRD)?
Both have evidence in TRD but the data types differ: ketamine/esketamine has multiple randomized trials and meta-analyses showing robust, rapid but often short-lived responses in many patients and is FDA-approved for TRD in the form of intranasal esketamine (FDA, 2019; McGirr et al., 2015). Psilocybin shows promising results in smaller randomized and open-label trials with some reports of durable remission for months after one or two supervised sessions, but larger phase III trials are ongoing to define its comparative effectiveness and durability (Carhart‑Harris et al., 2016; Davis et al., 2021).
What are the main safety concerns and side effects for each approach?
Ketamine commonly causes transient dissociation, elevated blood pressure and heart rate, nausea, and in repeated outpatient use there are concerns about cognitive effects and potential for misuse; monitoring during and after administration is standard (Zarate et al., 2006; FDA Spravato label, 2019). Psilocybin produces acute perceptual and psychological effects (intense emotions, disorientation, transient anxiety or fear), and is contraindicated in people with current psychosis or a family history of schizophrenia; persistent perceptual changes (HPPD) are rare but reported, and clinical protocols emphasize psychological support before, during and after dosing (Griffiths et al., 2016; Carhart‑Harris et al., 2016).
Are psilocybin and ketamine legal and available in clinical practice?
Ketamine (off‑label IV) and FDA‑approved intranasal esketamine (Spravato) are available in many clinical settings for TRD under supervised administration; esketamine received FDA approval in 2019 and comes with a Risk Evaluation and Mitigation Strategy (REMS) (U.S. FDA, 2019). Psilocybin remains a controlled substance in most countries and is not yet FDA‑approved for depression, though it has received Breakthrough Therapy designation and is being tested in multiple clinical trials and some jurisdictions have expanded clinical or research access (FDA Breakthrough Therapy summaries; ongoing phase II/III trials).
Can functional mushrooms (e.g., Lion’s Mane) or microdosing replace clinical psilocybin or ketamine treatment?
There is preliminary preclinical and small human trial evidence that Hericium erinaceus (Lion’s Mane) can support neurotrophic pathways and cognition, but high‑quality clinical data for treating major depression are limited and do not substitute for supervised psilocybin or ketamine therapy in TRD (small RCTs and animal studies; Nagano et al., 2010 and preclinical literature). Microdosing psychedelic compounds has mixed and largely inconclusive evidence from small or observational studies; it is not an FDA‑approved or established treatment for major depressive disorder, and people with severe or treatment‑resistant depression should seek evidence‑based clinical care (reviews of microdosing literature; systematic reviews ongoing).